Manufacture and evaluation of a HER2-positive breast cancer immunotoxin 4D5Fv-PE25

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) positive breast cancer is an aggressive subtype, accounting for around 20% of all breast cancers. The development of HER2-targeted therapy has substantially improved patient outcomes. Nevertheless, the increasing rate of side effects and re...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Yanjie, Wu, Zhengli, Pang, Zheng, Zhang, Lin, Song, Dandan, Liu, Fang, Li, Yanhong, Lin, Tongjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190103/
https://www.ncbi.nlm.nih.gov/pubmed/37198642
http://dx.doi.org/10.1186/s12934-023-02115-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190103/
https://www.ncbi.nlm.nih.gov/pubmed/37198642
http://dx.doi.org/10.1186/s12934-023-02115-0

Ejemplares similares